Pharmacokinetic Drug –Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer

ConclusionsOverall, the drug –drug interaction and safety profiles of trilaciclib in these studies support its continued use in patients with extensive-stage small-cell lung cancer.Clinical Trial RegistrationStudy 106: EudraCT number: 2019-002303-18; Study 114: not applicable; Study 03: Clinicaltrials.org: NCT02514447; August 2015.

Source: Clinical Drug Investigation - July 16, 2022 Category: Drugs & Pharmacology Source Type: research